Injective Launches the World’s First Decentralized Tesla Stock Futures Trading

January 13th, 2021 at 6:00 pm UTC · 2 min read

Injective Launches the World’s First Decentralized Tesla Stock Futures Trading

Photo: Injective Labs / Medium

We are thrilled to launch Tesla futures trading on Injective’s Solstice Pro Testnet! This marks the first time in history that Tesla futures can be traded in an entirely decentralized setting.

Background

Tesla is a rapidly growing Electric Vehicle company created by Elon Musk who recently became the wealthiest man on Earth.

The Tesla stock has also had a blockbuster year throughout 2020, becoming one of the best performing large cap stocks last year in the traditional markets. Tesla is by far the most traded stock by value on Wall Street, with $18 billion worth of its shares exchanged on average in each session over the past 12 months, easily beating Apple, in second place with average daily trades of $14 billion.

It is for this retail interest and high trading volumes that we have chosen Tesla to be the first futures market on Injective.

The Details

Injective Launches the World’s First Decentralized Tesla Stock Futures Trading

Live Tesla Stock Futures Market on Injective. Photo: Injective Labs / Medium

The first Tesla future on Injective will be live starting now on the Solstice Pro Testnet.

Expiration Date: March 26, 2021

Ticker: TSLA/USDT-0326

Over the coming weeks we plan to add a number of new stock futures on Injective so stay tuned!

About Injective Protocol

Injective Protocol is the first layer-2 decentralized exchange protocol that unlocks the full potential of decentralized derivatives and borderless DeFi. Injective Protocol enables fully decentralized trading without any restrictions, allowing individuals to trade on any derivative market of their choosing. Injective Protocol is backed by a prominent group of stakeholders including Pantera Capital, one of the most renowned venture capital firms in the world, and the leading cryptocurrency exchange, Binance.

Contact

Injective Protocol

[email protected]

Share: